Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | Determining the optimal use of targeted therapies in mantle cell lymphoma

Michael Williams • 10 Sep 2017
iwNHL 2017
Mantle Cell Lymphoma

With the rise of novel targeted therapies, it has become increasingly important to optimize treatment sequence and treatment combinations. Michael Williams, MD and his group at the Emily Couric Clinical Cancer Center, Charlottesville, VA have been focusing on developing an optimal strategy to use novel targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and Bcl-2 inhibitors, among others, as front-line therapy (either in combination or as chemotherapy replacements). Here, he discusses some of the challenges his team has faced.
Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC.

More from Michael Williams

Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma
4:15
Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma
Michael Williams • 12 Nov 2015
Panel discussion on new technologies in lymphoma - the applications of circulating tumor DNA
16:37
Panel discussion on new technologies in lymphoma - the applications of circulating tumor DNA
Ash Alizadeh et al. • 23 Sep 2016

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals